$QTTB
Q32 Bio Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004449 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $802.0K $1.677M $567.0K
YoY Change -18.16% 195.77% 28.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.78M $8.351M $8.420M
YoY Change 42.04% -0.82% 39.4%
% of Gross Profit
Research & Development $23.65M $23.99M $20.42M
YoY Change 1.92% 17.49% -20.53%
% of Gross Profit
Depreciation & Amortization $2.073M $2.099M $2.000M
YoY Change 0.63% 4.95% 17.65%
% of Gross Profit
Operating Expenses $34.43M $32.34M $28.84M
YoY Change 11.85% 12.13% -9.11%
Operating Profit -$30.66M -$28.27M
YoY Change 8.45% -9.64%
Interest Expense $42.00K $53.00K $40.00K
YoY Change 320.0% 32.5% -97.59%
% of Operating Profit
Other Income/Expense, Net $53.00K $41.00K
YoY Change 29.27% -97.53%
Pretax Income -$33.58M -$30.61M -$28.23M
YoY Change 12.73% 8.42% -4.72%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$33.58M -$30.61M -$28.23M
YoY Change 12.73% 8.42% -4.71%
Net Earnings / Revenue -4187.41% -1825.16% -4979.19%
Basic Earnings Per Share -$0.54
Diluted Earnings Per Share -$589.0K -$536.0K -$624.1K
COMMON SHARES
Basic Shares Outstanding 57.15M 57.11M
Diluted Shares Outstanding 57.11M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $155.9M $187.6M $178.0M
YoY Change -28.31% 5.37% -33.99%
Cash & Equivalents $108.4M $95.83M $178.0M
Short-Term Investments $47.49M $91.72M
Other Short-Term Assets $36.04M $4.266M $3.300M
YoY Change 1616.0% 29.27% -25.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $191.9M $191.8M $181.3M
YoY Change -12.6% 5.8% -33.85%
LONG-TERM ASSETS
Property, Plant & Equipment $2.252M $32.70M $39.68M
YoY Change -93.91% -17.61% -4.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.953M $1.274M $1.300M
YoY Change 50.23% -2.0% 0.0%
Total Long-Term Assets $19.81M $39.00M $47.10M
YoY Change -55.15% -17.2% 10.36%
TOTAL ASSETS
Total Short-Term Assets $191.9M $191.8M $181.3M
Total Long-Term Assets $19.81M $39.00M $47.10M
Total Assets $211.7M $230.8M $228.4M
YoY Change -19.72% 1.06% -27.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.366M $3.522M $3.300M
YoY Change -49.89% 6.73% -62.49%
Accrued Expenses $11.65M $11.98M $10.90M
YoY Change -5.27% 9.86% 39.74%
Deferred Revenue $3.208M $3.208M
YoY Change -43.04%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.23M $18.71M $17.20M
YoY Change -23.97% 8.75% -7.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $24.84M $13.54M $41.00M
YoY Change -44.91% -66.98% 1.74%
Total Long-Term Liabilities $24.84M $13.54M $41.00M
YoY Change -44.91% -66.98% 1.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.23M $18.71M $17.20M
Total Long-Term Liabilities $24.84M $13.54M $41.00M
Total Liabilities $42.07M $32.25M $58.10M
YoY Change -37.9% -44.5% -1.42%
SHAREHOLDERS EQUITY
Retained Earnings -$424.1M -$390.5M -$298.6M
YoY Change 29.16% 30.78% 70.14%
Common Stock $593.8M $589.1M
YoY Change 13.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $169.7M $198.6M $170.2M
YoY Change
Total Liabilities & Shareholders Equity $211.7M $230.8M $228.4M
YoY Change -19.72% 1.07% -27.91%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$33.58M -$30.61M -$28.23M
YoY Change 12.73% 8.42% -4.71%
Depreciation, Depletion And Amortization $2.073M $2.099M $2.000M
YoY Change 0.63% 4.95% 17.65%
Cash From Operating Activities -$30.43M -$25.39M -$28.89M
YoY Change 162.1% -12.13% 13.34%
INVESTING ACTIVITIES
Capital Expenditures -$338.0K -$477.0K -$160.0K
YoY Change -64.42% 198.13% -90.7%
Acquisitions
YoY Change
Other Investing Activities $44.00M $5.001M $39.00M
YoY Change -87.18% -441.81%
Cash From Investing Activities $43.66M $4.524M $38.84M
YoY Change -4695.89% -88.35% -395.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000K 379.0K 410.0K
YoY Change -100.0% -7.56% -33.87%
NET CHANGE
Cash From Operating Activities -30.43M -25.39M -28.89M
Cash From Investing Activities 43.66M 4.524M 38.84M
Cash From Financing Activities 1.000K 379.0K 410.0K
Net Change In Cash 13.23M -20.48M 10.36M
YoY Change -66.44% -297.72% -127.26%
FREE CASH FLOW
Cash From Operating Activities -$30.43M -$25.39M -$28.89M
Capital Expenditures -$338.0K -$477.0K -$160.0K
Free Cash Flow -$30.09M -$24.91M -$28.73M
YoY Change 182.29% -13.3% 20.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q3 fixx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
10016000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001661998
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38433
dei Entity Registrant Name
EntityRegistrantName
Homology Medicines, Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3468154
dei Entity Address Address Line1
EntityAddressAddressLine1
One Patriots Park
dei Entity Address City Or Town
EntityAddressCityOrTown
Bedford
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01730
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
301-7277
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
FIXX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
57150274
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95829000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217431000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
91722000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4266000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2133000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
191817000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
219564000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32697000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37002000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5028000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5897000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2501000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1274000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1274000
CY2021Q3 us-gaap Assets
Assets
230816000
CY2020Q4 us-gaap Assets
Assets
263737000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3522000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4722000
CY2021Q3 us-gaap Liabilities
Liabilities
32245000
CY2020Q4 us-gaap Liabilities
Liabilities
67742000
CY2020Q4 fixx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
9803000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1959000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3208000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5632000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
18705000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22658000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11582000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12941000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1958000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32143000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57150274
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50268666
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57149978
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50265575
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
589119000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
524358000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-390549000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-328368000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
198571000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
195995000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
230816000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263737000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1677000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
567000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
33169000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1722000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23987000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20417000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69439000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77197000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8351000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8423000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26054000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24986000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
32338000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
28840000
us-gaap Operating Expenses
OperatingExpenses
95493000
us-gaap Operating Expenses
OperatingExpenses
102183000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30661000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28273000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62324000
us-gaap Operating Income Loss
OperatingIncomeLoss
-100461000
CY2021Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
53000
CY2020Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
41000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
143000
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1558000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
53000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
143000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1558000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-30608000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-28232000
us-gaap Net Income Loss
NetIncomeLoss
-62181000
us-gaap Net Income Loss
NetIncomeLoss
-98903000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.19
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57106639
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45227231
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54704410
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45196459
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-30608000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-28232000
us-gaap Net Income Loss
NetIncomeLoss
-62181000
us-gaap Net Income Loss
NetIncomeLoss
-98903000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-183000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-183000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30615000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28243000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62186000
fixx Non Cash Lease Expense
NonCashLeaseExpense
869000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99086000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
258507000
CY2020Q1 fixx Stock Issued During Period Value Vesting Of Common Stock From Option Exercise
StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
12000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
135000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
537000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2883000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-202000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-35331000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
226541000
CY2020Q2 fixx Stock Issued During Period Value Vesting Of Common Stock From Option Exercise
StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
4000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3453000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
30000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-35340000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
194704000
CY2020Q3 fixx Stock Issued During Period Value Vesting Of Common Stock From Option Exercise
StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
5000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
401000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3346000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-11000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-28232000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
170222000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
195995000
CY2021Q1 fixx Stock Issued During Period Value Vesting Of Common Stock From Option Exercise
StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
4000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
143000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
446000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3883000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-23000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1073000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
200829000
CY2021Q2 fixx Stock Issued During Period Value Vesting Of Common Stock From Option Exercise
StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
4000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4473000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
25000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30500000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
224577000
CY2021Q3 fixx Stock Issued During Period Value Vesting Of Common Stock From Option Exercise
StockIssuedDuringPeriodValueVestingOfCommonStockFromOptionExercise
3000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
380000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4226000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-30608000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
198571000
us-gaap Profit Loss
ProfitLoss
-62181000
us-gaap Profit Loss
ProfitLoss
-98903000
us-gaap Depreciation
Depreciation
6280000
us-gaap Depreciation
Depreciation
5909000
fixx Non Cash Lease Expense
NonCashLeaseExpense
686000
us-gaap Share Based Compensation
ShareBasedCompensation
12582000
us-gaap Share Based Compensation
ShareBasedCompensation
9682000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-664000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
197000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-6000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2133000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-938000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1123000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
486000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
225000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
924000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-32609000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-590000
fixx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1901000
fixx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1655000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79321000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82720000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
97391000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
19991000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5000000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
228620000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2058000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2778000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-94449000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
205851000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
49744000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
825000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
938000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
145000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
160000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52168000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1098000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-121602000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
124229000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218705000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55048000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97103000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
179277000
fixx Reclassification Of Liability For Common Stock Vested In Noncash Transactions
ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions
12000
fixx Reclassification Of Liability For Common Stock Vested In Noncash Transactions
ReclassificationOfLiabilityForCommonStockVestedInNoncashTransactions
21000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
34000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
677000
fixx Property And Equipment Additions Included In Accrued Expenses And Other Liabilities
PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities
0
fixx Property And Equipment Additions Included In Accrued Expenses And Other Liabilities
PropertyAndEquipmentAdditionsIncludedInAccruedExpensesAndOtherLiabilities
126000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-183000
CY2018Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
24168656
us-gaap Net Income Loss
NetIncomeLoss
-62200000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-390500000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
fixx Investment Maturity Term
InvestmentMaturityTerm
less than one year
CY2021Q3 fixx Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.8%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, revenue recognition, accrued research and development expenses and useful lives assigned to property and equipment. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.</span></p>
CY2020Q3 fixx Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
95829000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
178003000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1274000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
1274000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97103000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179277000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
91727000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
91722000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2021Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2020Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
fixx Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
fixx Fair Value Assets Liabilities Transfer Between Levels
FairValueAssetsLiabilitiesTransferBetweenLevels
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55292000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53377000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22595000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16375000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32697000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37002000
CY2020Q3 us-gaap Depreciation
Depreciation
2000000.0
us-gaap Depreciation
Depreciation
5900000
CY2020Q3 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6684000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6902000
CY2021Q3 fixx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2534000
CY2020Q4 fixx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2393000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
572000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
291000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
226000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
217000
CY2021Q3 fixx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
10016000
CY2020Q4 fixx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
9803000
us-gaap Lessee Operating Sublease Option To Extend
LesseeOperatingSubleaseOptionToExtend
In 2018, the Company entered into a sublease agreement for the entire leased premises, which agreement was amended in September 2021 to extend the term of the sublease by approximately two weeks to be coterminous with the original lease
us-gaap Operating Lease Cost
OperatingLeaseCost
1869000
us-gaap Operating Lease Cost
OperatingLeaseCost
1869000
us-gaap Variable Lease Cost
VariableLeaseCost
1636000
us-gaap Variable Lease Cost
VariableLeaseCost
1689000
us-gaap Sublease Income
SubleaseIncome
705000
us-gaap Sublease Income
SubleaseIncome
685000
us-gaap Lease Cost
LeaseCost
2800000
us-gaap Lease Cost
LeaseCost
2873000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
914000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2987000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3077000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3169000
CY2021Q3 fixx Lessee Operating Lease Liability Payments Due After Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree
7197000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17344000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3803000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13541000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
2901000
us-gaap Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
2838000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.663
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.717
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.646
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.652
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.646
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.717
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.632
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.654
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0081
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0103
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0040
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0050
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0120
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0173
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5840824
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.18
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12278000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2053375
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.39
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
59465
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
303825
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
17.59
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7530909
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6607000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7530909
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
6607000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
600000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.73
fixx Unvested Common Shares Subject To Repurchase Vested
UnvestedCommonSharesSubjectToRepurchaseVested
2795
CY2021Q3 fixx Unvested Common Shares Subject To Repurchase Outstanding
UnvestedCommonSharesSubjectToRepurchaseOutstanding
296
CY2021Q3 fixx Unvested Common Shares Subject To Repurchase Outstanding
UnvestedCommonSharesSubjectToRepurchaseOutstanding
296
CY2020Q4 fixx Unvested Common Shares Subject To Repurchase Outstanding
UnvestedCommonSharesSubjectToRepurchaseOutstanding
3091
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4113985
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M18D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6092000
CY2020Q4 fixx Unvested Common Shares Subject To Repurchase Outstanding
UnvestedCommonSharesSubjectToRepurchaseOutstanding
3091
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4226000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3346000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12582000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9682000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7831405
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5816934

Files In Submission

Name View Source Status
0000950170-21-004449-index-headers.html Edgar Link pending
0000950170-21-004449-index.html Edgar Link pending
0000950170-21-004449.txt Edgar Link pending
0000950170-21-004449-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fixx-20210930.htm Edgar Link pending
fixx-20210930.xsd Edgar Link pending
fixx-20210930_cal.xml Edgar Link unprocessable
fixx-20210930_def.xml Edgar Link unprocessable
fixx-20210930_htm.xml Edgar Link completed
fixx-20210930_lab.xml Edgar Link unprocessable
fixx-20210930_pre.xml Edgar Link unprocessable
fixx-ex10_1.htm Edgar Link pending
fixx-ex31_1.htm Edgar Link pending
fixx-ex31_2.htm Edgar Link pending
fixx-ex32_1.htm Edgar Link pending
fixx-ex32_2.htm Edgar Link pending
img159367745_0.jpg Edgar Link pending
img159367745_1.jpg Edgar Link pending
img159367745_2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending